{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:42:36Z","timestamp":1777984956925,"version":"3.51.4"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":343,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mediators of Inflammation"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Aim<\/jats:title>\n                    <jats:p>Biologic disease\u2010modifying antirheumatic drugs (bDMARDs) are effectively used to relieve symptoms in inflammatory bowel diseases (IBD). The study aimed to examine the rate of non\u2010responders to bDMARD treatment in Australian population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Cohort studies using a 10% random sample of the population dispensing medicines under the Australian Pharmaceutical Benefits Scheme (PBS). People aged 18 years and over who initiated bDMARD for IBD in 2019 or 2020 were followed for 12 months. The proportion of non\u2010responders (people who discontinued initial therapy by Week 16 and 40) was determined using Kaplan\u2013Meier survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 522 initiators of bDMARD for Crohn\u2019s disease (mean age of 42 years). By Week 16, 15% discontinued initial therapy (primary non\u2010responders); 22% of initial responders discontinued bDMARD by Week 40 (secondary non\u2010responders). The primary non\u2010responder rate was lowest amongst infliximab initiators (6%), and highest for ustekinumab (24%). Infliximab had the lowest (17%) secondary non\u2010responder rate compared to the other biologics, suggesting less loss of response over time.<\/jats:p>\n                    <jats:p>There were 390 initiators of bDMARD for ulcerative colitis (UC) (mean age of 44 years). By Week 16, 25% discontinued initial therapy; 21% of people with initial response discontinued by Week 40. The non\u2010responder rates were lowest amongst vedolizumab initiators (5% for primary and 8% for secondary) and highest amongst adalimumab (50% for primary and 48% for secondary).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Comparison between bDMARD agents showed lowest initial non\u2010response and lowest loss of sustained response in infliximab initiators with Crohn\u2019s disease and in vedolizumab initiators with UC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1155\/mi\/6977602","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T05:18:57Z","timestamp":1765430337000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non\u2010Responders to Biologic Disease Modifying Antirheumatic Treatment for Inflammatory Bowel Diseases"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-7387","authenticated-orcid":false,"given":"Svetla","family":"Gadzhanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6811-8991","authenticated-orcid":false,"given":"Elizabeth","family":"Roughead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"e_1_2_13_1_2","volume-title":"Inflammatory Bowel Disease","author":"Digestive Health Foundation and Gastoenterology Society of Australia","year":"2013"},{"key":"e_1_2_13_2_2","volume-title":"Living With a Fistula","author":"Crohn\u2019s and Colitis UK","year":"2013"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2018.27"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.02.070"},{"key":"e_1_2_13_5_2","article-title":"Tumor Necrosis Factor-Alpha Antibody for Maintenance of Remission in Crohn\u2019s Disease","volume":"23","author":"Behm B.","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_13_6_2","unstructured":"Humira (Adalimumab) Australian Approved Product Information URL:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-03779-3."},{"key":"e_1_2_13_7_2","unstructured":"Remicade (Infliximab) Australian Approved Product Information URL:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2011-PI-03023-3&d=20230105172310101."},{"key":"e_1_2_13_8_2","unstructured":"Simponi (Golimumab) Australian Approved Product Information URL:https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-golimumab-rmc-170619-pi.pdf."},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2015.63"},{"key":"e_1_2_13_10_2","unstructured":"Entyvio (Vedolizumab) Australian Approved Product Information URL:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2014-PI-02140-1."},{"key":"e_1_2_13_11_2","unstructured":"Stelara (Ustekinumab) Australian Approved Product Information URL:https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP-2020-PI-02581-1&d=20230117172310101."},{"key":"e_1_2_13_12_2","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology Anatomical Therapeutic Chemical Code Classification index With Defined Daily Doses http:\/\/www.whocc.no\/atcddd\/."},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.155812"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21272"},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00312-5"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16436"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.008"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.08.027"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18006"}],"container-title":["Mediators of Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/mi\/6977602","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/mi\/6977602","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/mi\/6977602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:21:15Z","timestamp":1773008475000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/mi\/6977602"}},"subtitle":[],"editor":[{"given":"Jasbir","family":"Arora (RSS)","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/mi\/6977602"],"URL":"https:\/\/doi.org\/10.1155\/mi\/6977602","archive":["Portico"],"relation":{},"ISSN":["0962-9351","1466-1861"],"issn-type":[{"value":"0962-9351","type":"print"},{"value":"1466-1861","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"6977602"}}